Financial Wire

エメラルド・リソーシズ社、3月期に西オーストラリア州とカンボジアのプロジェクトを進展

-- エメラルド・リソーシズ(ASX:EMR)は、3月31日までの四半期において、西オーストラリア州のディンゴ・レンジ金プロジェクト、カンボジアのメモット金プロジェクト、オクヴァウ金鉱山、および探査鉱区で金鉱化を確認したと、火曜日にオーストラリア証券取引所に提出した書類で発表した。 ディンゴ・レンジ金プロジェクトでは、619メートル地点から最大45メートルにわたり、金品位4.1グラム/トン、うち641メートル地点から18.5メートルにわたり、金品位5.2グラム/トンが確認された。 同社は、1月の鉱物資源量推定以降、ディンゴ・レンジ金プロジェクトにおいて、露天掘りの拡張部分と地下採掘の可能性の両方を対象とした探査を実施してきたと述べた。 メモット金プロジェクトでは、40メートル地点から最大2メートルにわたり、金品位50.3グラム/トン、1メートル地点から最大14メートルにわたり、金品位3.4グラム/トンが確認されたと、同書類は付け加えている。オクヴァウ金鉱山における交差部は、347メートル地点で最大3メートル、金品位59グラム/トン、448メートル地点で最大22メートル、金品位1.9グラム/トンであった。

Related Articles

Asia

Huadian New Energy 2025 Profit Down 18%, Revenue Up 15%

Huadian New Energy (SHA:600930) posted 2025 attributable net profit of 7.26 billion yuan, down 18% from 8.83 billion yuan the previous year.Earnings per share slipped to 0.18 yuan from 0.24 yuan, according to a filing with the Shanghai bourse.Operating revenue rose 15% year over year to 39.0 billion yuan from 34.0 billion yuan.Shares of the power company were down 1% in recent trade.

$SHA:600930
Asia

National Storage REIT Says New South Wales Court Approves Brookfield, GIC Takeover Scheme

National Storage REIT (ASX:NSR) confirmed that the Supreme Court of New South Wales has approved the share scheme of arrangement and granted judicial advice for the trust scheme, enabling a Brookfield Funds and GIC-led consortium to proceed with the acquisition of all the company stapled securities, according to a Tuesday Australian bourse filing.The schemes are now legally effective following lodgment with the Australian Securities and Investments Commission, and the company's securities are expected to be suspended from trading at the close of trading on Tuesday, per the filing.The scheme record date is April 29, with implementation scheduled for May 8, when security holders will receive the scheme consideration, the filing added.

$ASX:NSR
Asia

Starpharma Says US FDA Supports First-in-Human Study of Cancer Radiotherapy Candidate; Shares Gain 7%

Starpharma Holdings (ASX:SPL) has received positive feedback from the US Food and Drug Administration (FDA) on the proposed design of its first-in-human phase 1 clinical study of the DEP HER2 radiotherapy candidate, according to a Tuesday filing with the Australian bourse.The company is developing the candidate to treat certain gastric/gastro-oesophageal junction cancers and other advanced cancers in patients who have previously received targeted therapy.The US FDA feedback supports plans to launch the phase one study, which is on track to begin in the second half of the year.The FDA also confirmed that the radiotherapy candidate is targeting a population with a significant unmet medical need, indicating the potential for a fast-track designation or other accelerated development pathways, Starpharma said.The company's shares were 7% higher in recent Tuesday trade.

$ASX:SPL